Late Breaking Abstract - Budget impact of introducing 12SQ HDM SLIT-tablet for house dust mite allergic asthma in Spain

Abstract

Introduction: 12SQ HDM SLIT-tablet (Acarizax®) is an oral lyophilisate house dust mite (HDM) standardised allergen extract, indicated for HDM allergic rhinitis and asthma, that has proved a reduction in time to first moderate/severe asthma exacerbations under ICS reduction Objectives: To estimate the cost implications of initiating the 12SQ HDM SLIT-tablet in mild and moderate partially controlled asthma patients in Spain Methods: A 3-year budget impact (BI) model was developed to explore the financial outcomes of use of the 12SQ HDM SLIT-tablet as add-on to maintenance medication, using Spanish epidemiological and patient management data. Inputs were obtained from literature and clinical expert opinion: allergic asthma prevalence, medical resources associated with management, exacerbations rate, and healthcare resource use associated with exacerbations. Based on unit costs for drug and medical resources, total costs in scenarios with and without the 12SQ HDM SLIT-tablet were determined to estimate the budget impact from a health provider perspective Results: The potential candidate population to receive the 12SQ HDM SLIT-tablet during three years was estimated at 3,291, 4,565 and 5,719, respectively. There would be a reduction in the cost of exacerbations of 660,331€ (1.8%), ranging from 1,678,696 to 484,774€ in the most and less favorable scenarios analyzed. Total budget, including drug cost, patient management and exacerbations would increase 2.73% (6,728,196€) the upper and lower values ranging from a 0.06% to a 3.02% Conclusions: The introduction of the 12SQ HDM SLIT-tablet in asthma has potential to reduce the budget impact of asthma exacerbations management in by 1.8%, with a limited total BI